Independent , Honest and Dignified Journalism

Personalised Cancer Vaccine Cuts Melanoma Recurrence Risk by 42% in Late-Stage Trial

Merck and Moderna report encouraging Phase 3 results for an experimental mRNA-based treatment combined with Keytruda, although longer-term survival data and regulatory approval remain pending.

NEW DELHI, October 26: An experimental personalised cancer vaccine developed by pharmaceutical companies Merck and Moderna has reduced the risk of melanoma recurrence or death by 42 per cent when combined with an existing immunotherapy, according to results from a major Phase 3 clinical trial released this month.

The findings from the INTerpath-001 study mark a significant development in research into personalised cancer treatment, which aims to use the genetic characteristics of an individual patient’s tumour to help the immune system recognise and attack cancer cells.

The investigational treatment, known as intismeran autogene, or V940, was evaluated alongside pembrolizumab, marketed by Merck as Keytruda. The combination was compared with Keytruda administered alongside a placebo in patients whose stage IIB to stage IV melanoma had been completely removed through surgery.

Detailed results announced on October 22 showed that patients receiving the combination experienced a 42 per cent reduction in the risk of recurrence or death compared with those receiving immunotherapy alone. The findings were subsequently presented at the European Society for Medical Oncology Congress 2026.

The study involved 1,137 patients and recorded a median follow-up period of 24.6 months. Researchers reported improvements in both recurrence-free survival and distant metastasis-free survival, two important measures used to assess whether cancer returns or spreads to other parts of the body.

The findings offer further evidence that personalised therapeutic vaccines could become an important addition to cancer treatment after surgery. However, the vaccine remains investigational, and the results do not establish that it can cure melanoma or guarantee that the disease will not return.

Two-year results show improved outcomes

According to the trial results, 82.2 per cent of patients receiving intismeran alongside Keytruda remained free from recurrence at two years. In the comparison group, which received Keytruda alone, the corresponding figure was 70 per cent.

The combination also reduced the risk of distant metastasis or death by 38 per cent relative to immunotherapy alone.

Distant metastasis occurs when cancer spreads from its original location to other organs or tissues. Preventing this progression is a central objective of treatment for patients with high-risk melanoma, even after the visible tumour has been removed.

The results are particularly relevant because patients with advanced-stage melanoma can remain at risk of relapse following apparently successful surgery. Additional treatment is often recommended to reduce that risk.

Keytruda is an immune checkpoint inhibitor that helps the body’s immune system recognise and attack cancer cells by blocking the PD-1 pathway. The personalised vaccine is intended to complement this approach by directing immune responses towards features specific to the patient’s tumour.

Researchers said the improvements were generally consistent across the patient groups assessed in the trial. Nevertheless, longer follow-up will be required to establish whether the benefits translate into improved overall survival.

How the personalised vaccine works

Unlike conventional preventive vaccines, which are designed to protect against infectious diseases, intismeran is a therapeutic cancer vaccine intended to help the immune system respond to an existing cancer.

The treatment is developed using information obtained from an individual patient’s tumour. Scientists analyse tumour-specific genetic mutations and identify targets known as neoantigens, which can help distinguish cancer cells from healthy tissue.

The resulting vaccine uses messenger RNA, or mRNA, to instruct cells to produce selected tumour-related targets. This is intended to train the immune system to recognise and respond to cancer cells carrying those features.

Because the genetic characteristics of tumours differ between patients, the vaccine is individually designed rather than produced as a single identical formulation for everyone.

The approach represents a shift towards precision medicine, in which treatment decisions and therapeutic products are tailored to the biological characteristics of an individual disease.

In the INTerpath-001 trial, patients received up to nine doses of the investigational vaccine at three-week intervals, alongside pembrolizumab. The treatment was administered after complete surgical removal of the melanoma.

The companies are investigating whether this combination can help the immune system identify cancer cells that may remain in the body even when there is no detectable tumour following surgery.

Researchers assess safety and treatment duration

The trial findings also provide information about the safety profile of the combination.

Treatment-related adverse events were reported in 95.8 per cent of patients receiving intismeran and Keytruda, compared with 90 per cent in the group receiving Keytruda alone. Severe treatment-related adverse events classified as grades 3 to 5 occurred in 14.2 per cent of the combination group and 13.4 per cent of the comparison group.

Commonly reported side effects among patients receiving the vaccine combination included fever, pain at the injection site and fatigue.

These findings will be important when regulators assess the treatment’s overall benefit-risk profile. The relatively small difference in severe adverse-event rates does not, by itself, establish that the combination is safer or more harmful; the nature, duration and clinical significance of individual events must also be considered.

The researchers also examined how the treatment’s benefits developed over time. During the first six months, outcomes for recurrence or death were broadly comparable between the two groups in the relevant analysis.

A prespecified sensitivity analysis found a greater treatment effect after the six-month vaccination period, with the combination associated with a 58 per cent lower risk of recurrence or death compared with Keytruda alone.

This result provides additional information about the possible timing of the treatment’s benefit, although it should not be interpreted as proof that every patient will experience the same response.

Overall survival remains an important unanswered question

While the recurrence and metastasis findings are encouraging, the overall survival data are not yet mature. Researchers therefore cannot yet determine conclusively whether the treatment combination helps patients live longer.

Recurrence-free survival measures the period during which a patient remains free from cancer returning, while overall survival measures how long patients live regardless of the cause of death.

Both are important, but they answer different questions. A treatment may delay recurrence without necessarily producing a measurable overall survival advantage within the same follow-up period.

Longer observation will help researchers determine whether the initial improvements persist, whether additional benefits emerge and how the treatment performs across different patient populations.

The trial remains ongoing to assess survival and other important outcomes. Further analysis will also help clarify the durability of the immune response and the potential need for additional treatment.

Regulatory review will determine availability

Merck and Moderna are expected to engage with regulators over potential applications for approval. However, the treatment cannot be assumed to be available for routine clinical use simply because the trial has reported positive results.

Regulatory authorities will need to review the clinical evidence, manufacturing processes, safety information and proposed conditions of use before deciding whether the vaccine combination should be approved.

The individualised manufacturing process may also present practical challenges. Each vaccine must be developed using information from the patient’s tumour, requiring specialised analysis and production rather than conventional large-scale manufacturing of an identical product.

Cost, access to molecular testing, production capacity and the time required to prepare individualised treatments could affect how widely the approach is adopted if approval is granted.

These questions will be particularly important for health systems seeking to make advanced cancer therapies accessible beyond major specialist hospitals.

Wider implications for cancer research

The findings are part of a broader effort to investigate whether personalised mRNA therapies can improve outcomes across different types of cancer.

Researchers are studying related approaches in several other tumour types, including kidney, bladder and lung cancers. Results from melanoma cannot automatically be applied to these diseases, as different cancers have distinct biological characteristics and may respond differently to immunotherapy.

The success of future studies will depend on whether personalised vaccines can produce meaningful clinical benefits, maintain an acceptable safety profile and offer advantages over existing treatments.

For melanoma patients, the latest data strengthen the case for continued research into treatments that target microscopic disease remaining after surgery. They also highlight the growing role of genetic analysis in guiding therapeutic development.

The results are promising, but further follow-up and regulatory assessment remain necessary before the experimental vaccine can be considered an established treatment option.

For now, specialists emphasise that patients should continue to discuss approved treatment choices, follow-up schedules and individual recurrence risks with their oncology teams rather than delaying established care in anticipation of an investigational therapy.

WhatsApp Channel